Merck Mercuriadis’ Hipgnosis Songs Fund released its first annual report today spelling out its financials since going public on 7/11.
Between 7/11 and 3/31, Merck’s company acquired 12 catalogs of just over 3,000 songs for £120m and since then have added another 10 catalogs—2,795 songs—at a cost of £121m. Revenue between 7/11 was 3/31 was £7.2m.
The company spelled out two of its revenue generators: The Bernard Edwards catalog generated $512,000 through sync licenses in April; and one song from The-Dream has pulled in $125,000 2019 to date.
“We focus on acquiring catalogs that are built around proven hit songs,” Mercuriadis wrote. “The key consideration from our due diligence is whether historical performance demonstrates that the songs’ earnings are predictable and reliable. These characteristics reduce risk and improve performance as they have long dated income streams that can be analyzed and forecasted.
“In addition, we are focused on helping the company to build a portfolio which produces a high proportion of copyright income derived from streaming.”
Total capital raised by the company now stands at £343.7m ($437.5m)—£202.2m from the IPO and £141.5m from a placing program issuance in mid-April that came mostly from existing institutional investors.
The company’s future target dividend yield is 5% per annum on the Ordinary Shares and the company intends to continue to pay four interim quarterly dividends.
The company will hold its general meeting on 9/10 in London.
NEAR TRUTHS: UNCORKED
Jay-Z's blingy mountain of cash keeps gaining altitude. (3/5a)
GRAMMY CHEW: THE
PRE-GRAMMY BOUNCE Let's hear it for ironic guitar-smashing. (3/5a)
| ||
BLACK HISTORY MONTH
A jazz chronicle of fighting the power.
GRAMMYS: WHERE TO FROM HERE?
After the snubs, the show.
ACQUITTED
In a phenomenal display of cowardice.
MOVING THE NEEDLE
When vaccination schedules and touring schedules meet.
|